Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

Antoni Sicras-Mainar,1 Ruth Navarro-Artieda2 1Dirección de Planificación, Badalona Serveis Assistencials SA, 2Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain Background: The aim of this study was to describe the clinical...

Full description

Bibliographic Details
Main Authors:	Sicras-Mainar A, Navarro-Artieda R
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-06-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/use-of-metformin-and-vildagliptin-for-treatment-of-type-2-diabetes-in--peer-reviewed-article-DDDT

Similar Items

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
by: Antoni Sicras-Mainar, et al.
Published: (2014-12-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
by: Antoni Sicras-Mainar, et al.
Published: (2015-02-01)

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients ( 2015;39:74-81)
by: Antoni Sicras-Mainar, et al.
Published: (2015-04-01)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
by: Serge Halimi, et al.
Published: (2008-06-01)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
by: Cakirca M, et al.
Published: (2014-02-01)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
by: Jong Ho Kim, et al.
Published: (2016-04-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
by: Paresh Ved, et al.
Published: (2012-01-01)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus′
by: Vishal Mundra
Published: (2012-01-01)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
by: Paresh Ved, et al.
Published: (2013-01-01)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
by: Sicras-Mainar A, et al.
Published: (2015-12-01)

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect
by: Hayder M Al-Kuraishy, et al.
Published: (2020-01-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-10-01)

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Combinación de metformina frente a inhibidores de la dipeptidilpeptidasa y sulfonilureas en el tratamiento de la diabetes tipo 2: impacto clínico y económico
by: Antoni Sicras-Mainar, et al.

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
by: Dejager S, et al.
Published: (2012-05-01)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
by: Grigorios Rombopoulos, et al.
Published: (2015-01-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin
by: Alima Almadiyeva, et al.
Published: (2018-12-01)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
by: Jun Sung Moon, et al.
Published: (2013-02-01)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus
by: Biswanath Sharma Sarkar, et al.
Published: (2019-02-01)

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
by: Hassoun AAK, et al.
Published: (2016-07-01)

Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-09-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN
by: V. K. Bayrasheva, et al.
Published: (2017-12-01)

Validación retrospectiva del Johns-Hopkins ACG Case-Mix System en la población Española Validating the Adjusted Clinical Groups [ACG] Case-mix System in a Spanish population setting: a multicenter study
by: Antoni Sicras-Mainar, et al.
Published: (2009-06-01)

Influencia de la sustitución de medicamentos de marca por genéricos en el cumplimiento terapéutico de la hipertensión arterial y la dislipidemia Influence of substitution of brand name for generic drugs on therapeutic compliance in hypertension and dyslipidemia
by: Antoni Sicras Mainar, et al.
Published: (2010-12-01)

Los adjusted clinicals groups: Un sistema de clasificación de pacientes por ajuste de riesgos
by: Antonio Sicras-Mainar, et al.
Published: (2013-06-01)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
by: Pan CY, et al.
Published: (2013-05-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
by: Klempfner Robert, et al.
Published: (2012-06-01)

Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial
by: Alessandra Schiappacassa, et al.
Published: (2020-10-01)

Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among Type 2 Diabetes Mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea
by: Kirandeep Kaur
Published: (2014-02-01)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
by: Lukashevich V, et al.
Published: (2013-01-01)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
by: A. Sicras-Mainar, et al.
Published: (2018-12-01)

Chromium (III) complexes of metformin, dapagliflozin, vildagliptin and glimepiride potentiate antidiabetic activity in animal model
by: Aktar, F., et al.
Published: (2021)